| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | 0.024 | 0.9 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.008 | 0.9 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | 0.03 | 0.9 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.9 |